MAY 24, 2019 1:02 PM PDT

What do parasitic fish have to do with cancer?

Have you ever seen a lamprey up close? If you haven’t, you should probably count your blessings, because these fish are terrifying to look at. With their jawless, tooth-filled mouths, a lamprey, which is a parasitic fish that resembles and eel and feeds on the blood of other fish, is enough to induce nightmares in adult humans.

Yet new research published in Science Advances suggests that lampreys might be the perfect vehicle for drugs that treat brain tumors, cancer, and even stroke. The research comes from a team of scientists at the University of Wisconsin-Madison and the University of Texas at Austin and analyzes a type of molecule from the immune system of lampreys, called "variable lymphocyte receptors" (VLRs).

VLRs are unique in their capacity to reach the extracellular matrix or ECM (think back to high school biology class!). "Similar to water soaking into a sponge, the lamprey molecules will potentially accumulate much more of the drug in the abundant matrix around cells compared to specific delivery to cells," explained co-author Professor John Kuo.

Because ECM networks compose a significant part of the central nervous system, the researchers think that VLRs are capable of transporting drugs to the brain more effectively for treatments for brain conditions, particularly in scenarios where the brain-blood barrier has been affected.

(Quick side note: in case you haven’t heard of the brain-blood barrier, it is a physiological aspect that stops potentially harmful agents leaking into the brain but also, therefore does not allow drugs to easily penetrate the brain. In the case of some health situations where the brain is affected, the brain-blood barrier becomes more permeable, which can lead to other problems but on the flip side but also allows drugs to get in.)

"Molecules like this [VLRs] normally couldn't ferry cargo into the brain, but anywhere there's a blood-brain barrier disruption, they can deliver drugs right to the site of pathology," explains lead author Professor Eric Shusta.

A lamprey, in all its glory. Photo: Phys.org

The researchers conducted their investigations on mouse models of glioblastoma, an aggressive form of brain cancer. They found that mice that received treatment of VLRs bound to doxorubicin, a drug used to treat this cancer, resulted in prolonged survival of the individuals. While more research is needed on this topic, the investigators are hopeful about what their findings could mean for future treatment methods.

Sources: Medical News Today, Science Advances

About the Author
  • Kathryn is a curious world-traveller interested in the intersection between nature, culture, history, and people. She has worked for environmental education non-profits and is a Spanish/English interpreter.
You May Also Like
MAR 09, 2021
Cannabis Sciences
Cannabis Alleviates Neuropathic Pain from Chemotherapy
MAR 09, 2021
Cannabis Alleviates Neuropathic Pain from Chemotherapy
Neuropathic pain from oxaliplatin-based chemotherapy regimens occurs in up to 90% of patients, and continued exposure to ...
MAR 10, 2021
Cancer
Changes to lung cancer screening guidelines
MAR 10, 2021
Changes to lung cancer screening guidelines
In a revision of a ten-year-old lung cancer screening guideline that initially recommended low-dose CT (LDCT) screening ...
MAR 19, 2021
Cancer
What does RNA editing do to the immune system?
MAR 19, 2021
What does RNA editing do to the immune system?
A recent study published in the journal Nature Communications from the University of Colorado Cancer Center explores new ...
APR 01, 2021
Immunology
Tumor-Killing 101: Vaccine Trains Immune Cells to Keep Skin Cancer at Bay
APR 01, 2021
Tumor-Killing 101: Vaccine Trains Immune Cells to Keep Skin Cancer at Bay
Cancer researchers have developed a therapeutic vaccine for melanoma, a deadly form of skin cancer. Instead of protectin ...
MAY 13, 2021
Cancer
Ovarian cancer screening doesn't save lives, reports new study
MAY 13, 2021
Ovarian cancer screening doesn't save lives, reports new study
New research published in the journal The Lancet highlights the eagerly awaited results of the UK Collaborative Trial of ...
MAY 31, 2021
Immunology
Engineering Faster, More Agile T Cell Cancer Fighters
MAY 31, 2021
Engineering Faster, More Agile T Cell Cancer Fighters
Cell therapies use engineered T cells extracted from the patient’s own immune system to rally an attack on tumors. ...
Loading Comments...